The third-generation CD47-SIRPα inhibitor HCB101 significantly inhibits tumor growth as monotherapy and demonstrates synergistic anti-tumor effects with anti-HER2 or anti-EGFR monoclonal antibodies [148]. This evidence concerns the gene SIRPA and neoplasm.